<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222283</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 057</org_study_id>
    <nct_id>NCT04222283</nct_id>
  </id_info>
  <brief_title>Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication</brief_title>
  <acronym>BICOLDER</acronym>
  <official_title>Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients infected and living with HIV are getting older and have more and more non-HIV&#xD;
      co-morbidities. These expose them to polypharmacy that increases the risk of pharmacological&#xD;
      interaction. Bictegravir, co-formulated with emtricitabine (FTC) and tenofovir alafenamide&#xD;
      (TAF) (BIKTARVY) a new generation integrase inhibitor with a high genetic barrier and had no&#xD;
      drug interaction may be a treatment of choice for participant over 65 years old who are HIV&#xD;
      infected . BIKTARVY improve adherence and quality of life; and on the other hand it would&#xD;
      limit the risks of pharmacological interaction. In addition, the use of TAF reducing the risk&#xD;
      of long-term renal toxicity and adverse effects on bone would be of interest in this aging&#xD;
      population and more at risk of osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1-infected patients over 65 years old at risk of polymedication HIV-1-infected adults&#xD;
      aged ≥ 65 years who are virologically-suppressed (HIV-1 RNA &lt;50 copies/mL) on a regimen&#xD;
      containing a pharmacokinetic enhancer as ritonavir or cobicistat Evaluate the antiviral&#xD;
      efficacy of 24 weeks treatment with the fixed dose combination(FDC) of TAF/FTC/BIC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological failure is defined by plasma HIV RNA &gt; 50 cps/mL on 2 following samples at 2 to 4 weeks apart</measure>
    <time_frame>Week 24</time_frame>
    <description>The primary outcome is the proportion of patients with virological failure at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Charlson and Fried Score</measure>
    <time_frame>Day 1, Week 24 and Week 48</time_frame>
    <description>• Assessment of co morbidities and frailty</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAD Score</measure>
    <time_frame>Day 1,Week 24 and Week 48</time_frame>
    <description>• Assessment of cardio vascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>polymedication</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>• Assessment of polymedication and potential drug-drug interactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug interactions</measure>
    <time_frame>Baseline To Week 48</time_frame>
    <description>• Change of drug-drug interactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• adverses events</measure>
    <time_frame>Baseline To Week 48</time_frame>
    <description>Rate of participants withdrawn from the study for grade 3 or 4 adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>therapeutic success</measure>
    <time_frame>Week 24 and Week 48</time_frame>
    <description>• Rate of therapeutic success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load detectable</measure>
    <time_frame>From Baseline to Week 48</time_frame>
    <description>• Rate of participants with detectable signal in case viral load is less than 20 c/ml threshold (Cobas/TaqmanHIV-1 Roche Diagnostics) at W24 and W48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blip detectable</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>• Rate of participants with a blip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mutation</measure>
    <time_frame>Day 1 to Week 48</time_frame>
    <description>• Emergence of resistance mutations at time of virological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunology parameters</measure>
    <time_frame>Baseline, to Week 24 and Week 48</time_frame>
    <description>• Change of CD4 and CD8 cell count from BSL,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid parameters</measure>
    <time_frame>Baseline, Week 24, Week 48</time_frame>
    <description>• Evolution of lipid parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal parameters</measure>
    <time_frame>Baseline,Week 4,Week 12,Week 24 and Week 48 ;</time_frame>
    <description>Renal glomerular filtration, creatinine clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacology</measure>
    <time_frame>Baseline, Week 12, Week 24, Week 48</time_frame>
    <description>• Plasma levels of antiretroviral drugs (TAF, FTC, BIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addherence</measure>
    <time_frame>Baseline, Week 24 and Week 48</time_frame>
    <description>• Adherence to treatment: self-administered questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>Week 4, Week 24 and Week 48</time_frame>
    <description>• Tolerance to treatment: questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal parameters (Urine)</measure>
    <time_frame>Baseline, Week 24, Week 48</time_frame>
    <description>urine albumin, urine creatinine, urine protein, beta-2-microglobulin and retinol binding protein</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>open label, multicentric, non randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one arm study to evaluate the safety and efficacy of switching from ritonavir- or cobicistat- booster containing regimens to a fixed-dose combination (FDC) of tenofovir alafenamide (TAF), emtricitabine (FTC) and bictegravir (BIC) in over 65 years old HIV-1-infected patients with virological suppression. Polymedications and drug-drug interactions will be analysed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIKTARVY 50Mg-200Mg-25Mg Tablet</intervention_name>
    <description>At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).</description>
    <arm_group_label>open label, multicentric, non randomized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1-infected patient&#xD;
&#xD;
          -  Age &gt; 65 years old&#xD;
&#xD;
          -  Plasma HIV RNA ≤ 50 copies/mL for ≥ 6 months: one blip between 50 et 200 cp/ml is&#xD;
             allowed in the past 6 months before screening.&#xD;
&#xD;
          -  Currently receiving an antiretroviral regimen containing a booster, ritonavir or&#xD;
             cobicistat&#xD;
&#xD;
          -  No resistance mutation to integrase inhibitors on cumulative HIV RNA genotype. The&#xD;
             reverse transcriptase resistant mutations M184V plus one TAM are allowed.&#xD;
&#xD;
          -  If no genotype is available, DNA genotype will be performed at screening visit: no&#xD;
             resistance mutation to integrase inhibitors, the reverse transcriptase resistant&#xD;
             mutations M184V plus one TAM are allowed.&#xD;
&#xD;
          -  Patient enrolled in or a beneficiary of a Social Security program (State Medical Aid&#xD;
             or AME is not a Social Security program)&#xD;
&#xD;
          -  Informed consent form signed by patient and investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-2 infection&#xD;
&#xD;
          -  Currently receiving one of the following drugs: Hypericum perforatum, rifampicin,&#xD;
             rifabutin, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, sucralfate,&#xD;
             cyclosporine, primidone, ténofovir et adéfovir.&#xD;
&#xD;
          -  Hemoglobin &lt; 10g/dL&#xD;
&#xD;
          -  Platelets &lt; 100 000/mm3&#xD;
&#xD;
          -  Hepatic transaminases AST and ALT &gt; 3x upper limit of normal (ULN)&#xD;
&#xD;
          -  Severe hepatic insufficiency (Child Pugh Class C)&#xD;
&#xD;
          -  Creatininemia clairance &lt; 30 mL/min (MDRD)&#xD;
&#xD;
          -  History or presence of allergy to the trial drugs or their components&#xD;
&#xD;
          -  Patients participating in another clinical trial including an exclusion period that is&#xD;
             still ongoing during the screening phase&#xD;
&#xD;
          -  Patients under judicial protection due to temporarily and slightly diminished mental&#xD;
             or physical faculties or under legal guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aïda BENALYCHERIF</last_name>
    <phone>40256365</phone>
    <phone_ext>331</phone_ext>
    <email>aida.benalycherif@imea.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>ISABELLE POZOT MARTIN</last_name>
      <phone>0491746163</phone>
      <phone_ext>334</phone_ext>
      <email>isabelle.poizot@mail.ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle POIZOT-MARTIN, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>CLOTILDE ALLAVENA</last_name>
      <phone>40083110</phone>
      <phone_ext>332</phone_ext>
      <email>clotilde.allavena@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>CLOTILDE ALLAVENA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Valentina ISERNIA, MD</last_name>
      <phone>40257057</phone>
      <phone_ext>331</phone_ext>
      <email>valentina.isernia@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>BAO PHUNG, MD</last_name>
      <phone>40257057</phone>
      <phone_ext>331</phone_ext>
      <email>bao.phung@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>YAZDAN YAZDANPANAH, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Gustave Dron</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>FAIZA AJANA</last_name>
      <phone>0320694617</phone>
      <phone_ext>333</phone_ext>
      <email>fajana@ch-tourcoing.fr</email>
    </contact>
    <investigator>
      <last_name>FAIZA AJANA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

